KRYS
Price
$132.73
Change
+$0.70 (+0.53%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
3.84B
67 days until earnings call
SNDX
Price
$11.16
Change
+$0.20 (+1.82%)
Updated
Jun 5, 04:59 PM (EDT)
Capitalization
960.29M
66 days until earnings call
Interact to see
Advertisement

KRYS vs SNDX

Header iconKRYS vs SNDX Comparison
Open Charts KRYS vs SNDXBanner chart's image
Krystal Biotech
Price$132.73
Change+$0.70 (+0.53%)
Volume$6.21K
Capitalization3.84B
Syndax Pharmaceuticals
Price$11.16
Change+$0.20 (+1.82%)
Volume$69.71K
Capitalization960.29M
KRYS vs SNDX Comparison Chart
Loading...
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
KRYS vs. SNDX commentary
Jun 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a StrongBuy and SNDX is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 06, 2025
Stock price -- (KRYS: $132.73 vs. SNDX: $11.16)
Brand notoriety: KRYS and SNDX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: KRYS: 65% vs. SNDX: 45%
Market capitalization -- KRYS: $3.84B vs. SNDX: $960.29M
KRYS [@Biotechnology] is valued at $3.84B. SNDX’s [@Biotechnology] market capitalization is $960.29M. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.31B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KRYS’s FA Score shows that 0 FA rating(s) are green whileSNDX’s FA Score has 1 green FA rating(s).

  • KRYS’s FA Score: 0 green, 5 red.
  • SNDX’s FA Score: 1 green, 4 red.
According to our system of comparison, KRYS is a better buy in the long-term than SNDX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KRYS’s TA Score shows that 6 TA indicator(s) are bullish while SNDX’s TA Score has 6 bullish TA indicator(s).

  • KRYS’s TA Score: 6 bullish, 2 bearish.
  • SNDX’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, KRYS is a better buy in the short-term than SNDX.

Price Growth

KRYS (@Biotechnology) experienced а +5.67% price change this week, while SNDX (@Biotechnology) price change was +5.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.85%. For the same industry, the average monthly price growth was +10.46%, and the average quarterly price growth was -0.86%.

Reported Earning Dates

KRYS is expected to report earnings on Aug 11, 2025.

SNDX is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+7.85% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KRYS($3.84B) has a higher market cap than SNDX($960M). SNDX (-15.582) and KRYS (-15.722) have similar YTD gains . KRYS has higher annual earnings (EBITDA): 140M vs. SNDX (-318.27M). KRYS has more cash in the bank: 617M vs. SNDX (516M). SNDX has less debt than KRYS: SNDX (1.84M) vs KRYS (9.66M). KRYS has higher revenues than SNDX: KRYS (333M) vs SNDX (43.7M).
KRYSSNDXKRYS / SNDX
Capitalization3.84B960M400%
EBITDA140M-318.27M-44%
Gain YTD-15.722-15.582101%
P/E Ratio31.83N/A-
Revenue333M43.7M762%
Total Cash617M516M120%
Total Debt9.66M1.84M526%
FUNDAMENTALS RATINGS
KRYS vs SNDX: Fundamental Ratings
KRYS
SNDX
OUTLOOK RATING
1..100
47
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
84
Overvalued
PROFIT vs RISK RATING
1..100
47100
SMR RATING
1..100
5795
PRICE GROWTH RATING
1..100
8990
P/E GROWTH RATING
1..100
973
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KRYS's Valuation (70) in the Pharmaceuticals Major industry is in the same range as SNDX (84) in the Biotechnology industry. This means that KRYS’s stock grew similarly to SNDX’s over the last 12 months.

KRYS's Profit vs Risk Rating (47) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNDX (100) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than SNDX’s over the last 12 months.

KRYS's SMR Rating (57) in the Pharmaceuticals Major industry is somewhat better than the same rating for SNDX (95) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than SNDX’s over the last 12 months.

KRYS's Price Growth Rating (89) in the Pharmaceuticals Major industry is in the same range as SNDX (90) in the Biotechnology industry. This means that KRYS’s stock grew similarly to SNDX’s over the last 12 months.

SNDX's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for KRYS (97) in the Pharmaceuticals Major industry. This means that SNDX’s stock grew significantly faster than KRYS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KRYSSNDX
RSI
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
75%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 3 days ago
82%
Declines
ODDS (%)
Bearish Trend 15 days ago
76%
Bearish Trend 22 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
68%
View a ticker or compare two or three
Interact to see
Advertisement
KRYS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SNDX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
IVFCX4.23N/A
N/A
Federated Hermes Intl Strat Val Div C
WFPAX45.52N/A
N/A
Allspring Special Mid Cap Value A
LMPOX31.74N/A
N/A
ClearBridge Small Cap Growth R
AFAVX13.55N/A
N/A
AMG River Road Focused Absolute Value I
PSCMX16.05N/A
N/A
Putnam Small Cap Value R6

KRYS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with ACLX. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then ACLX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KRYS
1D Price
Change %
KRYS100%
+0.86%
ACLX - KRYS
57%
Loosely correlated
+0.52%
IDYA - KRYS
56%
Loosely correlated
-2.50%
CGON - KRYS
54%
Loosely correlated
-0.78%
CRNX - KRYS
54%
Loosely correlated
+0.78%
XNCR - KRYS
53%
Loosely correlated
-0.44%
More